Charles Schwab Investment Management Inc Atea Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 635,282 shares of AVIR stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

635,282

Previous 607,882 4.51%

Holding current value

$2.05 Million

Previous $1.82 Million 25.87%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$2.55 - $3.6 $69,870 - $98,640	27,400 Added 4.51%	635,282 $2.29 Million
Q1 2025 Sep 15, 2025	SELL	$2.9 - $3.52 $79,460 - $96,448	-27,400 Reduced 4.31%	607,882 $1.82 Million
Q1 2025 May 09, 2025	SELL	$2.9 - $3.52 $149,770 - $181,790	-51,645 Reduced 7.83%	607,882 $1.82 Million
Q4 2024 Feb 06, 2025	BUY	$2.93 - $3.82 $27,454 - $35,793	9,370 Added 1.44%	659,527 $2.21 Million
Q3 2024 Nov 12, 2024	BUY	$3.17 - $4.02 $161,016 - $204,191	50,794 Added 8.47%	650,157 $2.18 Million
Q2 2024 Aug 12, 2024	SELL	$3.31 - $4.04 $42,884 - $52,342	-12,956 Reduced 2.12%	599,363 $1.98 Million
Q1 2024 May 08, 2024	BUY	$3.09 - $4.56 $86,498 - $127,648	27,993 Added 4.79%	612,319 $2.47 Million
Q4 2023 Feb 06, 2024	BUY	$2.8 - $3.35 $5,860 - $7,011	2,093 Added 0.36%	584,326 $1.78 Million
Q3 2023 Nov 08, 2023	BUY	$3.0 - $3.79 $24,822 - $31,358	8,274 Added 1.44%	582,233 $1.75 Million
Q2 2023 Aug 09, 2023	BUY	$3.21 - $5.06 $152,828 - $240,906	47,610 Added 9.05%	573,959 $2.15 Million
Q1 2023 May 11, 2023	SELL	$3.0 - $4.97 $114,435 - $189,580	-38,145 Reduced 6.76%	526,349 $1.76 Million
Q4 2022 Feb 13, 2023	BUY	$4.35 - $6.17 $48,589 - $68,918	11,170 Added 2.02%	564,494 $2.72 Million
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $689,560 - $1.1 Million	125,603 Added 29.37%	553,324 $3.15 Million
Q2 2022 Aug 15, 2022	BUY	$5.33 - $8.18 $69,950 - $107,354	13,124 Added 3.17%	427,721 $3.04 Million
Q1 2022 May 13, 2022	BUY	$5.5 - $9.19 $106,425 - $177,826	19,350 Added 4.9%	414,597 $2.99 Million
Q4 2021 Feb 11, 2022	BUY	$7.67 - $44.59 $15,861 - $92,212	2,068 Added 0.53%	395,247 $3.53 Million
Q3 2021 Nov 16, 2021	BUY	$21.33 - $35.06 $4.2 Million - $6.9 Million	196,840 Added 100.26%	393,179 $13.8 Million
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $2.07 Million - $6.35 Million	107,499 Added 121.0%	196,339 $4.22 Million
Q1 2021 May 17, 2021	BUY	$41.42 - $88.44 $99,656 - $212,786	2,406 Added 2.78%	88,840 $5.49 Million
Q4 2020 Feb 16, 2021	BUY	$26.36 - $41.78 $2.28 Million - $3.61 Million	86,434 New	86,434 $3.61 Million

Others Institutions Holding AVIR

# of Institutions

111

Shares Held

48.9M

Call Options Held

Put Options Held

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $268M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Atea Pharmaceuticals, Inc. Transaction History